We presented a male patient with a diagnosis of PD suffering from pathological gambling as an impulse control disorder due to antiparkinsonian drugs who did not respond to drug adjustments but showed complete improvement with sodium valproate, without any worsening in PD symptoms.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Sodium valproate is a well-known antiepileptic agent with multiple mechanisms of action such as sodium channel blockage and gamma-aminobutyric acid activity induction.
📊
Key Findings & Data:Despite its well-described anxiolytic and mood stabilization effects, its mechanism of action in pathological gambling is not clear.
💡
Conclusion & Impact:We presented a male patient with a diagnosis of PD suffering from pathological gambling as an impulse control disorder due to antiparkinsonian drugs who did not respond to drug adjustments but showed complete improvement with sodium valproate, without any worsening in PD symptoms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Sodium valproate is a well-known antiepileptic agent with multiple mechanisms of action such as sodium channel blockage and gamma-aminobutyric acid activity induction. Despite its well-described anxiolytic and mood stabilization effects, its mechanism of action in pathological gambling is not clear. However, it has been reported as an effective treatment option in pathological gambling for patients without Parkinson’s disease (PD). We presented a male patient with a diagnosis of PD suffering from pathological gambling as an impulse control disorder due to antiparkinsonian drugs who did not respond to drug adjustments but showed complete improvement with sodium valproate, without any worsening in PD symptoms.
🔖
Cite This Article
DEĞİRMENCİ, Y., KEÇECİ, H. (2019). Pathological gambling in a patient with Parkinson’s Disease and valproate response. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 32 - Sayı: 4, 365–367. https://ajindex.com/articles/151395
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30:1591-1601
Maloney EM, Djamshidian A, O’Sullivan SS. Phenomenology and epidemiology of impulsive compulsive behaviours in Parkinson’s disease, atypical Parkinsonian disorders and non-Parkinsonian populations. J Neurol Sci 2017; 374:47-52
Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2017; 64:1089-1096
Vriend C. The neurobiology of impulse control disorders in Parkinson’s disease: from neurotransmitters to neural networks. Cell Tissue Res 2018; 373:327-336
Ramirez-Zamora A, Gee L, Boyd J, Biller J. Treatment of impulse control disorders in Parkinson’s disease: practical considerations and future directions. Expert Rev Neurother 2016; 16:389-399
Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63:559-564
World Health Organization. International Classification of Diseases (ICD-10). Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992
Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 2006; 21:2068-2072
Zurowski M, O’Brien JD. Developments in impulse control behaviours of Parkinson’s disease. Curr Opin Neurol 2015; 28:387-392
Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol 2017; 133:679-717
Iancu I, Lowengrub K, Dembinsky Y, Kotler M, Dannon PN. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs 2008; 22:123-138
Montastruc JL, Sommet A, Olivier P, Bagheri H, Gony M, Lapeyre-Mestre M, Brefel-Courbon C, Ferreira J, Schmitt L, Senard JM, Rascol O. Drugs, Parkinson’s disease and Parkinsonian syndroms: recent advances in pharmacovigilance. Therapie 2006; 61:29-38. (French
Goodman WK, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 1997; 58(Suppl.5):32-49
Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psych